Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals

Gurnet Point Capital and Patient Square Capital Acquire Radius Health

June 23, 2022

Biotechnology

Gurnet Point Capital and Patient Square Capital completed a take-private acquisition of Radius Health, Inc. in a transaction valued at approximately $890 million (including debt), paying $10.00 per share in cash plus a $1.00 CVR tied to TYMLOS sales. Debt financing was provided by OrbiMed Advisors; following the transaction Radius will be delisted and will remain operating in the Boston, MA and Wayne, PA areas as a privately held biopharmaceutical company focused on bone health and neuro-orphan diseases.

Paratek Pharmaceuticals Acquires Optinose

May 21, 2025

Pharmaceuticals

Paratek Pharmaceuticals has completed its acquisition of Optinose, acquiring all outstanding shares for approximately $330 million including debt and contingent value rights. The deal, financed with capital from Paratek, B-FLEXION Life Sciences and Novo Holdings and debt financing from Oaktree, adds Optinose’s XHANCE product to Paratek’s specialty therapeutics portfolio.

Novartis AG Acquires Chinook Therapeutics

June 12, 2023

Biotechnology

Novartis AG agreed to acquire Chinook Therapeutics for $40 per share in cash, with contingent value rights of up to $4 per share tied to regulatory milestones —bringing total consideration to as much as approximately $3.5 billion. The acquisition, approved by both companies' boards, brings Chinook's kidney-disease pipeline into Novartis' renal portfolio and was expected to close in the second half of 2023 subject to customary conditions.

Pfizer Acquires Biohaven Pharmaceutical Holding Company Ltd.

October 3, 2022

Pharmaceuticals

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

Edgewater Capital Partners Acquires Naprotek

December 30, 2020

Manufacturing

Edgewater Capital Partners completed an investment to acquire Naprotek, a San Jose-based electronic manufacturing services (EMS) company specializing in quick-turn printed circuit board assembly for high-reliability applications. Patriot Capital provided subordinated debt and an equity co-investment alongside Edgewater and Naprotek's management team to support the transaction and future growth.

Merck to Acquire Harpoon Therapeutics for $680M

January 8, 2024

Biotechnology

Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.